Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of LN-144 (lifileucel) in Unresectable or Metastatic Melanoma
2017-000760-15Phase 2Unknown
- Sponsor
- Iovance Biotherapeutics
- Start
- Aug 2017
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lifileucel in melanoma, sponsored by Iovance Biotherapeutics. Primary endpoint: Objective Response Rate (ORR). Status: unknown.
02
Drugs
lifileucel
03
Conditions
melanoma
Beyond the preview
Go deeper on 2017-000760-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000760-15.